类风湿性关节炎(RA)是一种全身性炎症性疾病,RA最常见的关节外表现是肺部受累。间质性肺疾病(ILD)是类风湿性关节炎的常见并发症,发病率和死亡率都很高。目前,国际上对RA-ILD的最佳治疗方法尚未明确。对于RA-ILD患者,目标应该是缓解RA...类风湿性关节炎(RA)是一种全身性炎症性疾病,RA最常见的关节外表现是肺部受累。间质性肺疾病(ILD)是类风湿性关节炎的常见并发症,发病率和死亡率都很高。目前,国际上对RA-ILD的最佳治疗方法尚未明确。对于RA-ILD患者,目标应该是缓解RA和阻止ILD的进展。因此,了解RA-ILD的治疗方案的最新进展,这对改善患者预后至关重要。RA治疗包括常规合成的改善病情的抗风湿药物(DMARDs),生物合成DMARDs,以及靶向合成DMARDs,而这些药物也被常规用于对RA-ILD的治疗评估。本篇综述中不仅总结了上述药物用于RA-ILD最新进展,还评价了抗纤维化药物用于治疗RA-ILD的新进展。本文通过对这些药物的最新进展进行总结,为临床指导RA-ILD用药提供参考依据。Rheumatoid arthritis (RA) is a systemic inflammatory disease and the most common extra-articular manifestation of RA is pulmonary involvement. Interstitial lung disease (ILD) is a common complication of rheumatoid arthritis with high morbidity and mortality. Currently, the optimal treatment for RA-ILD is not well defined internationally. For patients with RA-ILD, the goal should be to alleviate RA and halt the progression of ILD. Therefore, it is important to be aware of the latest advances in treatment options for RA-ILD, which are essential for improving patient prognosis. RA treatments include conventional synthetic disease-modifying antirheumatic drugs (DMARDs), biosynthetic DMARDs, and targeted synthetic DMARDs, which are also routinely used for therapeutic evaluation of RA-ILD. In this review, we not only summarise the latest advances in the use of the above drugs for RA-ILD, but also evaluate the new advances in the use of antifibrotic drugs for the treatment of RA-ILD. By summarising the latest advances of these drugs, this article provides a reference basis for clinical guidance on the use of drugs for RA-ILD.展开更多
文摘类风湿性关节炎(RA)是一种全身性炎症性疾病,RA最常见的关节外表现是肺部受累。间质性肺疾病(ILD)是类风湿性关节炎的常见并发症,发病率和死亡率都很高。目前,国际上对RA-ILD的最佳治疗方法尚未明确。对于RA-ILD患者,目标应该是缓解RA和阻止ILD的进展。因此,了解RA-ILD的治疗方案的最新进展,这对改善患者预后至关重要。RA治疗包括常规合成的改善病情的抗风湿药物(DMARDs),生物合成DMARDs,以及靶向合成DMARDs,而这些药物也被常规用于对RA-ILD的治疗评估。本篇综述中不仅总结了上述药物用于RA-ILD最新进展,还评价了抗纤维化药物用于治疗RA-ILD的新进展。本文通过对这些药物的最新进展进行总结,为临床指导RA-ILD用药提供参考依据。Rheumatoid arthritis (RA) is a systemic inflammatory disease and the most common extra-articular manifestation of RA is pulmonary involvement. Interstitial lung disease (ILD) is a common complication of rheumatoid arthritis with high morbidity and mortality. Currently, the optimal treatment for RA-ILD is not well defined internationally. For patients with RA-ILD, the goal should be to alleviate RA and halt the progression of ILD. Therefore, it is important to be aware of the latest advances in treatment options for RA-ILD, which are essential for improving patient prognosis. RA treatments include conventional synthetic disease-modifying antirheumatic drugs (DMARDs), biosynthetic DMARDs, and targeted synthetic DMARDs, which are also routinely used for therapeutic evaluation of RA-ILD. In this review, we not only summarise the latest advances in the use of the above drugs for RA-ILD, but also evaluate the new advances in the use of antifibrotic drugs for the treatment of RA-ILD. By summarising the latest advances of these drugs, this article provides a reference basis for clinical guidance on the use of drugs for RA-ILD.
